Q BIOMED CLOSES LICENSING AGREEMENT FOR FDA APPROVED DRUG

Q BIOMED CLOSES LICENSING AGREEMENT FOR FDA APPROVED DRUG       Cancer palliation drug expected to start generating revenue in less than 12 months NEW YORK, September 7, 2016 — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company is pleased to announce the closing of an exclusive license and option agreement for a FDA approved […]

Read More

Q BIOMED PROVIDES UPDATE ON CORPORATE DEVELOPMENTS

Q BIOMED PROVIDES UPDATE ON CORPORATE DEVELOPMENTS Media Alert: CEO Interviewed on ‘The Stock Radio’ NEW YORK, September 1, 2016 — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company is pleased to report on its asset acquisition and an update on corporate development. While the summer months have been typically slow, we have made […]

Read More

Q BIOMED INC. ADVISOR AND MANNIN RESEARCH INC CSO DR SUSAN QUAGGIN ELEQUENTLY DISCUSSES GLAUCOMA AND MAN-01 WITH EYE ON VISION RADIO

Media Alert – Radio and Podcast Interview with Eye on Vision WYPL-FM 89.3 NEW YORK, July 14 2016 — Q BioMed Inc. (OTCQB: QBIO), partner Mannin Research Inc. CSO Dr. Susan Quaggin discusses glaucoma, treatment options, and her novel findings on the relationship between Tie2/TEK signaling, Schelmm’s Canal and glaucoma with Eye on Vision. In […]

Read More

NEW SNN Interview with Q BioMed Inc. CEO Mr. Denis Corin at the Marcum Microcap Conference June 2016

In this video interview, Mr. Corin and SNN host Robert Kraft discuss the following topics: Overview of Q BioMed Inc. Update since our last interview (Click here) Discusses recent news and catalysts New potential FDA approved Drug License Deal What differentiates QBIO from the competition Communicating the stories of projects under development Near-term goals and […]

Read More

Q BIOMED INC. REPORTS ON CURRENT AND NEW POTENTIAL ASSETS

New Near Term Revenue Asset Deal Pending and MAN-01 Drug Candidate Optimization and Selection Progressing on Schedule NEW YORK, June 1, 2016 — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company is pleased to report on new potential asset license/acquisition and an update on Man 01 development. We are pleased to announce that we […]

Read More

MANNIN RESEARCH TO PARTICIPATE AT ARVO 2016 MEETING

New York,  April 4,2016- Q BioMed Inc. (QBIO), a biotechnology acceleration company announces that its technology partner Mannin Research Inc. will be attending the Association for Research in Vision and Ophthalmology (ARVO), which takes place from May 1-5, 2016 in Seattle Washington. Mannin Research executives will be meeting with its vendors and research partners. The […]

Read More

Q BioMed Inc. To Present at the Global Chinese Financial Forum on April 30, 2016

Toronto, ON Conference Expects to attract over 200 participants New York, NY– (April 26, 2016)– Q BioMed Inc. (OTCQB: QBIO) a biotechnology acceleration company, today announced that the company will present at the Global Chinese Financial Forum (GCFF). The GCFF is the most prominent series of bi-lingual financial functions in both North America and China. […]

Read More

MANNIN RESEARCH TO PRESENT GLAUCOMA THERAPEUTICS TREATMENT AT MEDCITY INVEST CHICAGO APRIL 12 -13 2016

Management to Present Lead drug candidate to Industry and Venture Finance Executives NEW YORK, April 12, 2016 — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company is pleased to announce that its  license technology partner,  Mannin Research, will present at  MATTER Midwest University HealthTech Showcase on April 12 – 13th, 2016. Mannin Research will […]

Read More
Social media & sharing icons powered by UltimatelySocial